Comment on

• Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).

  Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, Ibata H, Kozuki T, Endo T, Tamura A, Kamimura M, Sakamoto K, Yoshimi M, Soejima Y, Tomizawa Y, Isa S, Takada M, Saka H, Kubo A. Kawaguchi T, et al. J Clin Oncol. 2014 Jun 20;32(18):1902-8. doi: 10.1200/JCO.2013.52.4694. Epub 2014 May 19. J Clin Oncol. 2014. PMID: 24841974 Clinical Trial.
• Erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer in the era of personalized medicine.

  Biswas B. Biswas B. J Clin Oncol. 2015 Feb 10;33(5):524. doi: 10.1200/JCO.2014.57.5621. Epub 2015 Jan 12. J Clin Oncol. 2015. PMID: 25584001 No abstract available.
• Alternative strategy to achieve increased overall survival and better quality of life in patients with second-line advanced non-small-cell lung cancer.

  Spitzer G, Socinski MA. Spitzer G, et al. J Clin Oncol. 2015 Feb 10;33(5):522-3. doi: 10.1200/JCO.2014.58.1603. Epub 2015 Jan 12. J Clin Oncol. 2015. PMID: 25584003 No abstract available.
• Epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR wild-type lung cancer: when there is a target, there is a targeted drug.

  Zhou F, Chen X, Zhou C. Zhou F, et al. J Clin Oncol. 2015 Feb 10;33(5):523-4. doi: 10.1200/JCO.2014.57.5449. Epub 2015 Jan 12. J Clin Oncol. 2015. PMID: 25584007 No abstract available.